NCT04734028

PTRG-DES Consortium

Platelet Function and genoType-Related Long-term progGosis in DES-treated Patients : A Consortium From Multi-centered Registries

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 13,160 (actual)
• Sponsor: Gyeongsang National University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The PTRG-DES consortium is a coalition composed of multi-center, real-world registries including CAD patients treated with DES in South Korea. From 9 academic registries in Korea, a total of 13,160 patients were enrolled for this database between July 2003 and August 2018. The aim of the study was to investigate long-term prognostic implications of platelet function and genotypes after DES implantation for significant CAD in South Korea.

Detailed description

The investigators enrolled patients treated with DES during DAPT including clopidogrel who had at least one of VerifyNow test (PRU and ARU) and genotyping. In this consortium, the investigators tried to find the unique characteristics of East Asians based on platelet function, genotype and inflammatory markers.

Conditions

• Coronary Artery Disease
• Clopidogrel, Poor Metabolism of
• Platelet Dysfunction
• Stent Thrombosis

Interventions

Type	Name	Description
DRUG	Clopidogrel Tablets	DES-treated patients were treated with clopidogrel 75 mg daily and aspirin 100 mg daily

Timeline

• Start date: 2003-07-09
• Primary completion: 2018-08-07
• Completion: 2020-06-30
• First posted: 2021-02-02
• Last updated: 2022-03-31

Locations

1 site across 1 country: South Korea

Regulatory

• FDA-regulated drug study